The National Institute for Health and Care Excellence (NICE) and the Canadian Agency for Drugs and Technology in Health (CADTH) have announced that they will offer a combined advisory service to help companies prepare for Health Technology Assessments (HTA), predicated on the commonalities of their assessment regimes.
This service will serve a similar function to NICE’s existing Scientific Advice service, and provide expert feedback on clinician and health economic development plans, so that companies can generate the necessary evidence to support their HTA submissions. It will also allow companies to develop clinical trials that satisfy the requirements of both jurisdictions, streamlining their development process.
“This new collaboration with CADTH uses the synergies between the English and Canadian systems and provides companies with comprehensive and practical advice from both countries through a single, streamlined process.”
– Jeanette Kusel, Director of NICE Scientific Advice
The announcement follows the news a fortnight ago that NICE and CADTH, along with the US’s Institute for Clinical and Economic Review (ICER), are to collaborate on a project developing methods to assess high-cost drugs.